Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-Label, Multicenter Study of I-124 Evuzamitide as an Imaging Agent for the Diagnosis of Cardiac Amyloidosis Using Positron Emission Tomography Computed Tomography (PET/CT)

NCT06788535 is registered in ClinicalTrials.gov with Sharmila Dorbala as lead sponsor.

NCT NCT06788535
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06788535 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-Label, Multicenter Study of I-124 Evuzamitide as an Imaging Agent for the Diagnosis of Cardiac Amyloidosis Using Positron Emission Tomography Computed Tomography (PET/CT)
Lead sponsor
Sharmila Dorbala
Phase
Phase 3
Overall status
Completed
Start date
January 14, 2025
Completion date
April 9, 2026
Enrollment
204 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

cardiac amyloidosis